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Background: Ischemic stroke patients are prone to infection by stroke-induced immunodepression. We hypothesized
that levels of lipopolysaccharide binding protein (LBP), interleukin-10 (IL-10), IL-6 and C-reactive protein (CRP) are early
predictors for the development of stroke-associated infection.
Methods: Fifty-six patients with ischemic stroke (n = 51) and transient ischemic attack (TIA) (n = 5) who presented
within 6 hours after symptom onset and who were free of detectable infection on admission were included in the
study. Of these, 20 developed early infections during the first week. Blood samples were taken at 6, 12, and 24 hours
and at 3 and 7 days after stroke onset. Levels of LBP, Il-10, IL-6 and CRP, as well as S100B, were measured as markers of
inflammation and brain damage by commercially available immunometric tests.
Results: In the univariate analysis, levels of LBP, IL-10, IL-6 and CRP significantly differed between patients who
developed an infection and those who did not. In the binary logistic regression analysis, which was adjusted for
National Institutes of Health Stroke Scale (NIHSS) on admission, stroke subtype and S100B peak levels, as indicator of
the extent of brain damage, IL-10 at 6 hours, CRP at 6 hours and NIHSS on admission were identified as independent
predictors of infection (IL-10: P = 0.009; CRP: P = 0.018; NIHSS: P = 0.041). The area under the curve (AUC) of the
receiver operating characteristic (ROC) curves in relation to the dichotomized status of the infection (infection versus
no infection) was 0.74 (95% confidence interval: 0.59 to 0.88) for CRP at 6 hours, 0.76 (0.61 to 0.9) for IL-10 at 6 hours,
0.83 (0.71 to 0.94) for NIHSS on admission and 0.94 (0.88 to 1) for the combination of CRP, IL-10 and NIHSS. In a
subanalysis, 16 patients with early infections were matched with 16 patients without infection according to S100B
peak levels. Here, the temporal pattern of LBP, IL-10, IL-6 and CRP significantly differed between the patient groups.
Conclusions: Our data show that blood levels of inflammation markers may be used as early predictors of
stroke-associated infection. We propose prospective studies to investigate if the calculated cut-offs of CRP,
IL-10 and NIHSS might help to identify patients who should receive early preventive antibiotic treatment.
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After acute ischemic stroke, urinary tract infections or
pneumonia often complicate the clinical course and
worsen the outcome [1]. Infections occurring within the
first week after stroke onset are regarded as stroke-
associated. They are correlated with stroke severity, since,
on the one hand, a severe neurological deficit may facili-
tate infection and on the other hand severe infections
may trigger neurological worsening.
Experimental and clinical studies have shown that a
pronounced anti-inflammatory response may cause a
state of stroke-induced immunodeficiency [2,3] via
mechanisms that include the hypothalamic pituitary ad-
renal axis, the sympathetic nervous system and the vagus
nerve (for a review see [4,5]). Thereby, stroke patients
might be at a higher risk of infections. Clinical studies
found increased levels of the anti-inflammatory cytokine
Interleukin-10 (IL-10) in patients with post-stroke infec-
tion [6,7]. But also pro-inflammatory mediators such as
C-reactive protein (CRP) and Interleukin-6 (IL-6) are
increased in ischemic stroke patients who develop an
infection [6,8].
Lipopolysaccharide-binding protein (LBP) is essential
for the response to bacterial lipopolysaccharides. As a
type I acute phase response protein, it is also produced
in acute inflammation for a review see [9]. Recently, LBP
levels have been shown to be increased in stroke patients
with infection [10].
Considering the worse outcome in patients with post-
stroke infection, the prevention of infections by early
application of antibiotics has repeatedly been discussed.
So far, respective studies have shown controversial re-
sults. According to a meta-analysis that included five
clinical studies, antibiotics reduced neither the fre-
quency of dependency nor death [11]. However, early
identification of patients at risk for infection by mo-
lecular markers might improve selection criteria for
preventive antibiotic treatment and, thereby, treatment
effects. We hypothesized that early levels of the inflam-
matory and anti-inflammatory markers LBP, IL-10, IL-6
and CRP are biomarker candidates for the prediction of
post-stroke infections in acute ischemic stroke patients.
Methods
Study population
Between August 2007 and February 2009, 56 patients
with acute ischemic stroke (n = 51) or transient ischemic
attack (TIA) (n = 5), who were admitted to the stroke unit
of the Department of Neurology at Hannover Medical
School, Germany within 6 hours after symptom onset,
were enrolled. The patient cohort derived from a cohort
of a former study [12]. Ischemic stroke was defined as an
acute-onset focal neurological deficit combined with neu-
roimaging evidence of cerebral infarction by cranialcomputed tomography (CCT) or magnetic resonance im-
aging (MRI). TIA was defined as a transient episode of
neurological dysfunction caused by focal brain ischemia
without acute infarction. Exclusion criteria were history
of malignant tumour, hemorrhagic stroke, any detectable
infection prior to stroke onset or any immunosuppressive
treatment for example, dexametasone. Post-stroke infec-
tion was defined as any infection occurring within the
first week after the event. Patients were examined for
signs of infection (that is, productive cough, tachypnea,
dysuria, flank pain or fever) as part of the daily ward
round by the treating physician. At the beginning of clin-
ical symptoms, a diagnostic workup was performed in-
cluding clinical, laboratory and radiological examination
(for example, chest radiograph or abdominal ultrasound
imaging). The criteria used for diagnosis and anti-
infective therapy were according to the local clinical
practice. In the study population, post-stroke infection
was identified (median interval from stroke onset to the
diagnosis of infection was 3 days) in 20 patients.
On admission, clinical and demographic data of the pa-
tients, including age, sex, stroke etiology classified accord-
ing to Trial of Org 10172 in Acute Stroke Treatment
(TOAST) criteria [13], white blood cell count (WBC), cre-
atinine, estimated glomerular filtration rate (evaluated by
CKD-EPI equation), vascular risk factors (arterial hyper-
tension, diabetes mellitus, hyperlipidemia, and smoking
status) and intravenous treatment with recombinant
tissue-type plasminogen activator (rt-PA) were recorded.
Initial stroke severity was evaluated by the National
Institutes of Health Stroke Scale (NIHSS) at admission.
Clinical outcome was assessed by NIHSS at 90 days.
The study was approved by the appropriate ethics gov-
erning board (ethics committee Hannover Medical School).
Patients or relatives gave written informed consent.
Blood sampling and marker quantification
Serum, EDTA- and heparin-plasma samples were drawn
from patients at 6, 12 and 24 hours and 3 and 7 days after
onset of symptoms. The samples were immediately cen-
trifuged at 1,600 × g for 15 minutes (Thermo Scientific
Heraeus Multifuge 3SR plus Centrifuge). The super-
natant was stored at -80°C until analysis.
All biochemical parameters were measured using com-
mercially available CE (Communautés Européennes)-cer-
tified reagents for clinical laboratory diagnostics following
manufacturers’ instructions. IL-6, CRP and S100B were
determined in serum samples using the Immulite 2000 for
IL-6 (two point calibration with calibrators 0116L6PL and
0116L6PH, Siemens Healthcare Diagnostics, Eschborn,
Germany), the BN II nephelometric analyzer for high sen-
sitivity CRP (hsCRP) (seven point calibration with N
Rheumatology Standard SL, Siemens Healthcare Diagnos-
tics), in the case of hsCRP values >40 mg/l the cobas6000







Female 11 (55.0) 19 (52.8) 0.873
Malea 9 (45.0) 17 (47.2)
Age (years)b 78 (63; 83) 70 (62; 79) 0.141
Stroke subtype 0.006c
Cardiogenic embolisma 13 (65.0) 7 (19.4)
Large artery occlusiona 2 (10.0) 10 (27.8)
Lacunar infarctiona 1 (5.0) 9 (25.0)
Unknowna 4 (20.0) 10 (27.8)
Hypertensiona 17 (85.0) 22 (61.1) 0.062
Smokera 4 (20.0) 5 (13.9) 0.551
Hyperlipoproteinemiaa 6 (30.0) 14 (39.9) 0.506
Creatinine (μmol/L)b 76 (63; 87) 80 (69; 96) 0.293
eGFR (ml/min per 1.73 m2)b 78 (60; 88) 71 (60; 90) 0.918
Diabetes mellitusa 8 (40.0) 8 (22.2) 0.158
NIHSS on admissionb 15 (9; 18) 3 (1; 8) <0.001c
NIHSS 90db 6 (3; 34) 1 (0; 3) <0.001c
WBC 1d (1000/μl)b 8.2 (6.6; 8.8) 7.2 (6.4; 8.1) 0.074
S100B peak levels (μg/l)b 0.21 (0.12; 0.69) 0.11 (0.09; 0.24) 0.011c
i.v. rt-PAa 6 (30.0) 9 (25.0) 0.686
eGFR, estimated glomerular filtration rate; NIHSS, National Institutes of Health
Stroke Scale; i.v. rt-PA, intravenous recombinant tissue-type plasminogen acti-
vator; WBC, white blood cell count.Data are presented as numbers (percent-
ages) a or median (interquartile range) b. P <0.05 was considered statistically
significant c.
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tor, Roche Diagnostics, Mannheim Germany) and the
cobas e411 analyzer for S100B (two point calibration with
S100 CalSet, Roche Diagnostics). LBP was measured in
EDTA-plasma and IL-10 in heparin-plasma using the
Immulite 2000 for LBP (two point calibration with calibra-
tors LLBL0116 and LLBH0116, Siemens Healthcare Diag-
nostics) and the Immulite 1000 for IL-10 (two point
calibration with calibrators LXPL0114 and LXPH0114,
Siemens Healthcare Diagnostics).
The interassay precision was 6.5% for IL-6, 5.5% for
Il-10, 5.0% for S100B, 4.0% for CRP, and 5.6% for LBP.
The intra-assay precision was 4.5% for IL-6, 3.1% for
IL-10, 2.1% for S100B, 4.6% for CRP and 3.2% for LBP.
Statistics
Data were analyzed using SPSS software package ver-
sion 11.5, SigmaPlot 11.0 and R version 3.1.1 with the
package pROC [14]. Baseline characteristics are shown
as percentages or median with interquartile range. The
differences of demographics, clinical characteristics and
blood marker levels between stroke patients with and
without infection were detected by Mann-Whitney U-
test (continuous variables) or Chi-Square-test (propor-
tions). The binary logistic regression analysis included
initial levels of IL-10, IL-6 and CRP adjusted for NIHSS
on admission, stroke subtype, and peak levels of S100B,
using the method of backward stepwise. Receiver Oper-
ating Characteristic (ROC) curves and the correspond-
ing area under the curve (AUC) were computed for
CRP at 6 h, IL-10 at 6 h and NIHSS on admission and
also for the combination of the three markers. Random
forests (RF) were used to combine the three single bio-
markers. In order to avoid overfitting, scores for the
ROC curves of the combination of the biomarkers were
calculated on the basis of jackknife or leave-one-out
method, so that the random forest did not use the cor-
responding patient for training. Other classifiers like lin-
ear discriminant analysis (LDA) and support vector
machines (SVM) yielded similar results. In a subanaly-
sis, for comparison of time courses of marker levels, 16
patients with infection and 16 without infection were
matched according to S100B peak levels (differences in
levels <20%, respectively). Between-group comparisons
were analyzed by the Mann-Whitney test, and within-
group comparisons between initial (6 h) and follow-up
time points were analyzed by Friedman test and
Wilcoxon test. For within group comparisons, after
Bonferroni correction for multiple testing, a probability
value ≤0.01 was considered statistically significant. The
relation between marker levels was assessed by Spear-
man rank correlation analysis. After Bonferroni correc-
tion for multiple testing, a probability value ≤0.003 was
considered statistically significant.Results
Demographics
The study population consisted of 56 patients. Stroke-
associated infection was diagnosed in 20 of these pa-
tients. Demographic and clinical characteristics for pa-
tients with and without infection are shown in Table 1.
Here, patients differed significantly for stroke subtype,
clinical severity (NIHSS on admission), clinical outcome
(NIHSS at day 90), and the extent of brain damage
(S100B peak levels). The infections were pneumonia (n =
9), urinary tract infection (n = 10), and cholangitis (n = 1).
Levels of LBP, IL-10, IL-6 and CRP differed in patients with
and without infection
In the univariate analysis, levels of LBP, IL-10, IL-6 and
CRP were compared between patients with and without
infection (Table 2). LBP differed significantly between
12 hours and 7 days (12 h, 24 h, 3 d: P <0.001; 7 d: P =
0.019), while IL-10 levels differed significantly during the
first day (6 h: P = 0.002; 12 h, 24 h: P < 0.001). IL-6 and
CRP levels were significantly different at each time point
(IL-6 6 h, 12 h, 24 h, 3 d, 7 d: P < 0.001; CRP 6 h: P =
0.004; 12 h, 24 h, 3 d, 7 d: P < 0.001).
Table 2 LBP, Il-10, Il-6 and CRP in patients with and
without infection
Infection No infection P
(n = 20) (n = 36)
LBP 6 h (μg/ml)a 6.37 (4.81; 8.74) 5.57 (4.79; 6.77) 0.194
LBP-12 h (μg/ml)a 8.29 (6.53; 10.41) 5.45 (4.77; 6.44) <0.001b
LBP 24 h (μg/ml)a 10.95 (9.40; 15.50) 6.27 (4.99; 7.19) <0.001b
LBP 3 d (μg/ml)a 9.83 (8.78; 16.50) 6.09 (5.14; 7.65) <0.001b
LBP 7 d (μg/ml)a 7.93 (5.89; 13.10) 6.13 (4.83; 7.75) 0.019b
IL-10 6 h (pg/ml)a 4.0 (2.2; 6.7) 2.0 (1.5; 3.1) 0.002b
IL-10 12 h (pg/ml)a 4.2 (2.9; 6.4) 2.2 (1.6; 2.8) <0.001b
IL-10 24 h (pg/ml)a 3.9 (3.0; 5.0) 2.3 (2.0; 2.9) <0.001b
IL-10 3 d (pg/ml)a 2.8 (2.4; 5.5) 2.7 (2.0; 3.3) 0.109
IL-10 7 d (pg/ml)a 3.3 (2.5; 6.4) 2.8 (2.2; 3.5) 0.178
IL-6 6 h (ng/l)a 18 (8; 28) 4 (3; 8) <0.001b
IL-6 12 h (ng/l)a 18 (10; 34) 4 (3; 9) <0.001b
IL-6 24 h (ng/l)a 16 (8; 27) 4 (3; 8) <0.001b
IL6 3 d (ng/l)a 14 (8; 36) 3 (3; 6) <0.001b
IL-6 7 d (ng/l)a 14 (6; 20) 4 (3; 6) <0.001b
CRP 6 h (mg/l)a 4.94 (1.79; 10.13) 2.50 (1.07; 3.21) 0.004b
CRP 12 h (mg/l)a 7.85 (5.16; 13.90) 2.42 (1.05; 3.84) <0.001b
CRP 24 h (mg/l)a 19.60 (9.45; 31.83) 2.7 (1.48; 4.82) <0.001b
CRP 3 d (mg/l)a 25.50 (11.80; 59.00) 2.24 (1.24; 5.55) <0.001b
CRP 7 d [mg/l)a 9.97 (8.49; 50.00) 2.01 (1.19; 4.33) <0.001b
Data are presented as median (interquartile range) a. P <0.05 was considered
statistically significant b.
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with infection
For determination if initial levels (at 6 h) of IL-10, IL-6
and CRP are independently associated with infection in
ischemic stroke patients, we performed a binary logistic
regression analysis that was adjusted for NIHSS on ad-
mission, stroke etiology, and peak levels of S100B. The
analysis revealed that IL-10 at 6 h, CRP at 6 h and
NIHSS on admission are independently associated with
infection (IL-10: P = 0.009; CRP: P = 0.018; NIHSS:
P = 0.041) (Table 3).Table 3 Independent early determinants of infection after
acute ischemic stroke
Parameters Β SE P value
IL-10a 3.328 0.461 0.009
CRPb 2.136 0.320 0.018
NIHSSc 1.192 0.086 0.041
Binary logistic regression including IL-6, IL-10 a and CRP b at 6 hours, stroke
severity (National Institutes of Health Stroke Scale (NIHSS) on admission) c,
stroke subtype and peak levels of S100B as indicator of the extent of
brain damage.Prediction of infection by initial CRP, IL-10 and National
Institutes of Health Stroke Scale
After identification of CRP at 6 h and IL-10 at 6 h and
NIHSS on admission as independent determinants of infec-
tion, ROC analyses were performed (Figure 1. A-D). The
area under the curve (AUC) for CRP in relation to dichoto-
mized status of infection (infection versus no infection) was
0.74 (95% confidence interval: 0.59 to 0.88), 0.76 (95% con-
fidence interval: 0.61 to 0.9) for IL-10 and 0.83 (95% confi-
dence interval: 0.71 to 0.94) for NIHSS (Figure 1. A-C). For
the combination of CRP and NIHSS the AUC was 0.86
(95% confidence interval: 0.77 to 0.96), 0.87 (95% confi-
dence interval: 0.76 to 0.98) for IL-10 and NIHSS and 0.94
(95% confidence interval: 0.88 to 1) for CRP, IL-10 and
NIHSS, when the method of RF was used (Figure 1. D). For
a specificity of 97% the ROC curve-derived sensitivity was
60% for the combination of CRP, IL-10 and NIHSS. Results
using the method of LDA or SVM for the combination
were comparable.
Comparison of time courses of LBP, IL-10, IL-6 and CRP in
patients with and without infection
For comparison of time courses of LBP, IL-10, IL-6 and
CRP 16 patients with infection and 16 without infection
were matched for S100B peak levels (differences in levels
<20%, respectively) because the extent of the unspecific
systemic inflammatory response after ischemic stroke de-
pends on the size of brain damage. Of note, in 4 out of 20
patients with infection, no fitting matches could be identi-
fied according to S100B levels. Clinical characteristics did
not differ between both patient groups (P >0.05). Fig-
ure 2A-D demonstrates the time courses. The temporal
pattern differed significantly for each marker between the
patient groups; levels in patients with infection were sig-
nificantly elevated (LBP 12 h: P = 0.001, 24 h: P <0.001,
3 d: P = 0.007; IL-10 6 h: P = 0.006, 12 h: P <0.001, 24 h:
P= 0.004; IL-6 6 h: P <0.001, 12 h: P <0.001, 24 h: P= 0.004,
3 d: P = 0.003, 7 d: P= 0.008; CRP 6 h: P= 0.007, 12 h:
P <0.001, 24 h: P <0.001, 3 d: P <0.001, 7 d: P= 0.002).
For within-group comparisons of marker levels be-
tween initial (6 h) and follow-up time points, a signifi-
cant increase was detected in patients with infection for
LBP (6 h versus 12 h: P = 0.001, 6 h versus 24 h: P =
0.001, 6 h versus 3 d: P = 0.01) and CRP (6 h versus
12 h: P = 0.002, 6 h versus 24 h: P = 0.001, 6 h versus 3
d: P = 0.002). In patients without infection, marker levels
significantly increased for LBP (6 h versus 24 h: P =
0.005, 6 h versus 3 d: P = 0.005, 6 h versus 7 d: P =
0.007) and CRP (6 h versus 24 h: P = 0.001).
Correlation between LBP, IL-10, IL-6 and CRP in patients
with and without infection
The correlation analysis revealed a significant correlation
between LBP and CRP at 6 h (P <0.001), 12 h (P = 0.003)
Figure 1 A-D Receiver operating characteristic (ROC)-curves of initial CRP, IL-10 and National Institutes of Health Stroke Scale (NIHSS)
for prediction of infection. A: CRP: area under the curve (AUC) = 0.74 (95% confidence interval: 0.59 to 0.88), B: IL-10: AUC = 0.76 (95%
confidence interval: 0.61 to 0.9), C: NIHSS: AUC = 0.83 (95% confidence interval: 0.71 to 0.94), D: Combination of CRP, IL-10 and NIHSS: AUC = 0.94
(95% confidence interval: 0.88 to 1) according to the method of RF (random forests) with the jackknife/leave-one-out method to compute the
scores. The gray areas indicate 95% confidence regions for the ROC curves.
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IL-6 and CRP at 7 d (P = 0.001) in patients with infec-
tion (Table 4). In patients without infection LBP versus
IL-6 at 3 d (P = 0.003) and IL-6 versus CRP at 3 d (P =
0.003) were significantly correlated (Table 4).
Discussion
The main findings of the present study are that, in
acute stroke patients, levels of LBP, IL-10, IL-6 and
CRP show a different time course in patients with and
without post-stroke infection and that IL-10 and CRP
at 6 h and NIHSS on admission are independent pre-
dictors of stroke-associated infections.
After the acute event of stroke, concentrations of the
pro-inflammatory cytokine IL-6 and the acute phase
protein CRP in brain tissue and peripheral blood are in-
creased since they are rapidly released by activated cells[12,15]. Also, in the acute stage after stroke, a strong
anti-inflammatory reaction results in a suppression of
the immune system [5]. As a mechanism, immunode-
pression is hypothesized to favor the development of
infections, for example, from microaspiration to pneu-
monia or from asymptomatic bacteriuria to urinary tract
infection. IL-10 is a major player of the cellular and mo-
lecular suppression of inflammation [16]. Our data show
that levels of the pro- and anti-inflammatory markers
IL-6, CRP and IL-10 differ as early as at 6 h after stroke
onset between patients with and without post-stroke in-
fection. In patients with infection, levels remained ele-
vated until 24 h in the case of IL-10 and until day 7 in
the case of IL-6 and CRP, respectively.
In contrast to this, early levels of LBP at 6 h after stroke
were not significantly associated with occurrence of infec-
tion. At later time points, LBP levels were significantly
Figure 2 A-D Temporal profile of LBP, IL-10, IL-6 and CRP in patients with and without infection. Comparison of time courses between
patients with (n = 16) and patients without (n = 16) infection matched for S100B peak levels for the extent of brain damage. Data are presented
as median with interquartile range. Intergroup comparisons between patients with and without infection: *P ≤0.05; **P ≤0.01; ***P ≤0.001.
Within-group comparisons of marker levels between initial (6 h) and follow-up time points: Patients with infection: significant differences were
detected for LBP (6 h versus 12 h: P = 0.001, 6 h versus 24 h: P = 0.001, 6 h versus 3 d: P = 0.01) and CRP (6 h versus 12 h: P = 0.002, 6 h versus
24 h: P = 0.001, 6 h versus 3 d: P = 0.002). Patients without infection: significant differences were detected for LBP (6 h versus 24 h: P = 0.005,
6 h versus 3 d: P = 0.005, 6 h versus 7 d: P = 0.007) and CRP (6 h versus 24 h: P = 0.001).
Table 4 Correlation between LBP, IL-10, IL-6 and CRP in patients with and without infection
6 h 12 h 24 h 3 d 7 d
R P R P R P r P r P
Infection (n = 16)
LBP versus IL-10 −0.405 0.120 −0.314 0.237 −0.284 0.286 0.100 0.712 0.041 0.879
LBP versus IL-6 −0.018 0.948 0.376 0.151 0.292 0.273 0.322 0.224 0.281 0.292
LBP versus CRP 0.879 <0.001a 0.697 0.003a 0.450 0.080 0.820 <0.001a 0.571 0.021
IL-10 versus IL-6 −0.014 0.959 0.221 0.411 0.309 0.244 0.399 0.126 0.785 <0.001a
IL-10 versus CRP −0.393 0.132 −0.247 0.356 −0.084 0.757 0.424 0.102 0.361 0.170
IL-6 versus CRP 0.078 0.774 0.302 0.255 0.336 0.204 0.427 0.099 0.725 0.001a
No infection (n = 16)
LBP versus IL-10 0.194 0.471 0.195 0.469 0.030 0.913 −0.233 0.384 0.183 0.498
LBP versus IL-6 0.028 0.929 0.426 0.100 0.252 0.346 0.687 0.003a 0.297 0.264
LBP versus CRP 0.478 0.061 0.453 0.078 0.178 0.509 0.444 0.085 0.615 0.011
IL-10 versus IL-6 −0.279 0.296 −0.037 0.893 −0.379 0.148 −0.326 0.218 0.270 0.313
IL-10 versus CRP 0.100 0.712 0.010 0.970 0.187 0.489 0.055 0.841 0.072 0.791
IL-6 versus CRP 0.280 0.293 0.402 0.122 0.407 0.117 0.689 0.003a 0.308 0.247
P ≤ 0.003 was considered statistically significant a.
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we showed that LBP - as an acute-phase protein – not
only increases in patients with infection but also increases
in patients without infection during the first day in re-
sponse to the infarction. Further investigations need to
show whether the increase of LBP in circulating blood
directly results from the site of infarction or represents a
systemic reaction from peripheral blood cells.
Over the past years, several clinical trials have investigated
preventive anti-infective treatment not only for lowering the
rate of infection but also for ameliorating the clinical out-
come. Mechanisms that may explain why the rate of infec-
tion could directly influence neurological outcome are the
potentially detrimental effects of hyperthermia, hypotension
or hypoxia on neurons [17-19]. So far, only the Mannheim
Infection in Stroke Study (MISS) has reached improvement
for rate of infection and clinical outcome using the prophy-
lactic mezlocillin plus sulbactam in severe stroke patients,
who presented as bedridden within 24 h of stroke onset
[20]. In contrast to these results, other clinical trials investi-
gating treatment with anti-infective drugs have failed to im-
prove outcome [21] or did not lower the rate of infection
[22]. Acute ischemic stroke patients had significantly better
outcome at 30 d when treated with minocycline within 24 h
compared to placebo [23]. The favorable outcome after ad-
ministration of minocycline has been recently confirmed in
another cohort of stroke patients [24]. But it has been dis-
cussed that minocycline acts independently from its anti-
biotic effects via neuroprotection.
So far, it remains unclear as to whether an assessment
of molecular inflammation markers or clinical variables
might be useful for decision-making in preventive anti-
infective treatment. Recently, the predictive ability of
both, IL-6 and CRP within 3 days after stroke for post-
stroke infection has been reported [25,26]. However, the
time points used for the determination of inflammation
markers might be too late to indicate the development of
infection. In two of the clinical studies investigating
preventive anti-infective treatment, the association of in-
flammation markers and post-stroke infections was ana-
lyzed. In the Preventive Antibacterial Therapy in Acute
Ischemic Stroke (PANTHERIS) trial Klehmet et al. [27]
showed that increased levels of IL-10 were predictive
for post-stroke infections independently of preventive
antibacterial treatment with moxifloxacin. Therefore, the
authors concluded that IL-10 levels might indicate
patients who would not respond to this treatment. Also,
increased IL-10 levels within 24 h were associated with
infection in patients from the Early Systemic Prophylaxis
of Infection after Stroke (ESPIAS) trial, a randomized
clinical trial using preventive antibacterial treatment with
levofloxacin [6].
Since timing is decisive in acute stroke treatment, early
administration of antibiotics in a selected cohort ofstroke patients might be the key to ameliorate outcome.
Therefore, in contrast to former studies, we determined
very early levels of inflammation markers IL-6, IL-10,
CRP and LBP (at 6 h) to analyze the association with
post-stroke infection. Of note, the multivariate analysis
revealed an independent association of IL-10 and CRP
with infections, suggesting a strong effect of the inflam-
matory and anti-inflammatory reaction on the develop-
ment of infections.
In a subanalysis of patients matched for S100B levels,
we showed that differences in inflammation markers in
patients with and without infection were independent
from the extent of brain lesion. As previously shown, de-
velopment of infection is associated with stroke severity
[28,29]. The association of stroke severity and infection
can be explained since clinical deficits result in condi-
tions such as dysphagia or shallow respiration due to
disturbance of consciousness. But severe stroke does not
obligatorily mean large infarction, as reflected by S100B
peak levels, since a small infarction in the brainstem or
internal capsule is related to a severe deficit, whereas a
major infarction in the temporal and occipital lobe may
be associated with only a mild deficit. In the current
study, we found evidence for an additional independent
effect of the individual inflammatory response of any pa-
tient on the development of early infection. According
to our data, we propose prospective studies to investi-
gate if the combination of markers CRP, IL-10 and
NIHSS might be useful as inclusion criteria for very
early initiation of preventive anti-infective treatment.
Limitations
However, the current study has some limitations. The
number of patients studied is rather small considering
the multifactorial pathology of ischemic stroke, but we
collected serial blood samples in all patients in order to
present the temporal pattern of the studied markers. An-
other limitation is that only samples from peripheral
blood could be achieved. The source of increased marker
levels might be either peripheral blood cells or resident
cells at the site of infarction. In addition, concentrations
of inflammation markers at the site of infarction may
only partially be reflected in the peripheral blood. How-
ever, cerebrospinal fluid, which might better represent in-
flammation processes in the brain tissue, cannot be
achieved repetitiously and staying on schedule for the
lumbar puncture would be difficult. Also, despite exclu-
sion of patients with history of infection prior to stroke
or with early signs of infection at inclusion, it cannot be
ruled out that infections with only subclinical symptoms
developed prior to inclusion. Finally, larger studies need
to confirm the combination of markers for independent
prediction of early infection. In addition, so far it remains
unclear whether biomarker measurement with kits other
Worthmann et al. Journal of Neuroinflammation  (2015) 12:13 Page 8 of 9than the ones used in the current study could reproduce
the findings.
Conclusions
The current study shows that the temporal pattern of
circulating levels of LBP, IL-10, IL-6 and CRP differs
between acute ischemic stroke patients with and without
post-stroke infection. IL-10 and CRP at 6 h, as well as
NIHSS on admission, were identified as independent pre-
dictors of stroke-associated infection. Prospective studies
are warranted to confirm these surrogate markers as in-
dependent early predictors for infection in acute ischemic
stroke patients. This might help to identify patients who
should receive early preventive antibiotic treatment.
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